PAREXEL REPORTS FIRST QUARTER FISCAL 2004 FINANCIAL RESULTS
BOSTON, MA, October 21, 2003 — PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the first quarter ended September 30, 2003.
For the three months ended September 30, 2003, PAREXEL’s consolidated service revenue was $129.8 million compared with $119.4 million in the prior year period, a year-over-year increase of 8.7%. Operating income in the first quarter was $7.8 million versus $7.0 million in the prior year quarter. Operating income as a percentage of service revenue was 6.0% for the first quarter of Fiscal Year 2004 versus 5.9% for the first quarter of Fiscal Year 2003. Net income for the first quarter ended September 30, 2003 was $4.7 million, or $0.18 per diluted share, compared with net income of $3.3 million, or $0.13 per diluted share in the comparable prior year period.
On a segment basis, service revenue for the first quarter of Fiscal 2004 was $79.7 million in Clinical Research Services (CRS), $21.8 million in the PAREXEL Consulting Group (PCG), $20.2 million in Medical Marketing Services (MMS), and $8.1 million in Perceptive Informatics, Inc (PII).
Mr. Josef H. von Rickenbach, PAREXEL’s Chairman and Chief Executive Officer stated, “The year-over-year improvement in the performance of the CRS business was a major contributor to the increase in the Company’s overall gross margin which came in at 35.7% of service revenue, up from 33.0% in the September quarter last year. We are also pleased to report that the Company met consensus expectations of $0.18 per share, a 38.5% increase over the comparable prior year period.”
The Company issued forward-looking guidance regarding revenue and earnings per share for the second quarter of Fiscal 2004 (ending December 31, 2003), and for Fiscal 2004. For the second quarter of Fiscal 2004, the Company anticipates reporting consolidated service revenue in the range of $132 to $137 million and earnings per diluted share in the range of $0.19 to $0.20. For Fiscal 2004, consolidated service revenue is expected to be in the range of $550 to $570 million and earnings per diluted share are projected to range between $0.80 to $0.88.
The financial charts within this press release contain reclassifications of certain prior period numbers, which were made for business reasons and had no impact to the Company’s combined revenue, expenses, or operating income from a historical perspective. The reclassifications relate to shifts made between Direct Costs and Selling, General, and Administrative expenses, and to certain revenue and expense items that were moved from the PCG business into the MMS business. Historic financials have also been reclassified back to Fiscal 2002 and may be found in the Investor Relations section of the Company’s website at www.PAREXEL.com under “Additional Financials”.
PAREXEL’s First Quarter Fiscal 2004 Earnings Conference Call will begin at 10 a.m. today and will be broadcast live over the Internet via webcast. The webcast may be accessed in the “Webcasts” portion of the Investor Relations section of the Company’s website at http://www.parexel.com. Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed. A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for one year following the live event. To participate via telephone, dial (612) 332-0523 and ask to join the PAREXEL quarterly conference call.
PAREXEL is one of the largest biopharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), Clinical Trial Management Systems (CTMS), electronic diary and investigator database solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. PAREXEL’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 57 locations throughout 36 countries around the world, and has 5,105 employees.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding the Company’s existing capital resources and future cash flows from operations, and statements regarding expected financial results, future growth and customer demand, such as the guidance provided by the Company with respect to the second quarter of Fiscal Year 2004 and the full Fiscal Year 2004. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", “estimates”, “projects” and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2003 as filed with the Securities and Exchange Commission on September 15, 2003, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.